voxelotor
Commercial- Indications
- Sickle cell disease
Company intelligence / Profile preview
Global Blood Therapeutics
South San Francisco, California, United Statespfizer.com ↗
- Ownership
- Private
- Employees
- ~444
- Development stage
- Commercial
01
Overview
Global Blood Therapeutics developed Oxbryta® (voxelotor), the first FDA-approved oral therapy that directly inhibits hemoglobin polymerization—the root cause of red blood cell sickling in SCD. Approved by the FDA in November 2019 for patients aged ≥12 years and subsequently expanded to younger pediatric populations. The company also advanced a robust pipeline including GBT601 and inclacumab—both with orphan drug designations—targeting different aspects of SCD pathophysiology. In October 2022, Pfizer acquired GBT for $5.4 billion to expand its rare hematology portfolio[3][7][8].
- Therapeutic areas
- HematologyPulmonologyRare Diseases
- Modalities
- small molecules (notably Oxbryta/voxelotor and pipeline assets)monoclonal antibodies (inclacumab)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Sanofi – acquisition/licensing of two additional sickle cell compounds[9]
Beyond the preview
Go deeper on Global Blood Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Global Blood Therapeutics.